Format

Send to

Choose Destination
HIV Med. 2001 Jan;2(1):59-60.

L-Carnitine in the treatment of HIV-associated lipodystrophy syndrome.

Author information

1
Specialized practice for HIV and Hepatogastroenterology, Duesseldorf, Germany. maussst@compuserve.com

Abstract

The objective of this pilot study was to assess the effect of L-carnitine on the course of the HIV-associated lipodystrophy syndrome. Twelve patients presenting with combined atrophic and hypertrophic changes of body fat were treated with L-carnitine 1000 mg bid for 3 months. No marked improvement of the body changes was observed. However a reduction in serum cholesterol levels, but not triglycerides, was noted. These preliminary data do not support the use of L-carnitine for the rapid reversal of advanced fat tissue alterations due to HIV-associated lipodystrophy.

PMID:
11737377
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center